•
Jun 30, 2024
Vaxart Q2 2024 Earnings Report
Vaxart announced its Q2 2024 financial results, highlighting a BARDA contract for COVID-19 program and progress in clinical and regulatory goals.
Key Takeaways
Vaxart reported its Q2 2024 financial results, securing a significant BARDA contract of up to $453 million for a Phase 2b trial of its oral COVID-19 vaccine. The company also reported positive Phase 1 data for its bivalent norovirus vaccine candidate and extended its cash runway.
Received a BARDA contract providing up to $453 million to support a Phase 2b trial for the oral COVID-19 vaccine candidate.
Reported positive Phase 1 data from the bivalent norovirus vaccine candidate in lactating mothers.
Extended cash runway through strategic financial management.
Preparing to initiate the COVID-19 Phase 2b trial, pending regulatory alignment with the FDA.